Aminoglycoside-induced ototoxicity

Current Pharmaceutical Design

Volumn 13, Issue 1, 2007, Pages 119-126

  Selimoglu, Erol ^a  

^a INONU UNIVERSITY   (Turkey)

Author keywords

Aminoglycosides; Ototoxicity

Indexed keywords

2,3 DIHYDROXYBENZOIC ACID; AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIOXIDANT; CASPASE; DEFEROXAMINE; DIHYDROSTREPTOMYCIN; FAS ANTIGEN; GENTAMICIN; IRON CHELATING AGENT; KANAMYCIN; METHIONINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEOMYCIN; NETILMICIN; NEUROTROPHIN; REACTIVE OXYGEN METABOLITE; RIBOSOME RNA; SALICYLIC ACID; SISOMICIN; STREPTOMYCIN; STRESS ACTIVATED PROTEIN KINASE; TETRACYCLINE; THIOCTIC ACID; TOBRAMYCIN; TUMOR NECROSIS FACTOR RECEPTOR 1;

ATAXIA; CLINICAL TRIAL; COCHLEA INJURY; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; EAR INFECTION; ENZYME ACTIVATION; EXCITOTOXICITY; GENE MUTATION; GENETIC PREDISPOSITION; HEARING; HEARING IMPAIRMENT; HEARING LOSS; HETEROZYGOTE; HIGH RISK POPULATION; HUMAN; INCIDENCE; INNER EAR DISEASE; LOW DRUG DOSE; MENIERE DISEASE; META ANALYSIS; NONHUMAN; NYSTAGMUS; OSCILLOPSIA; OTOTOXICITY; OXIDATIVE STRESS; PATHOGENESIS; PRIMARY PREVENTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; SIDE EFFECT; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; TINNITUS; VESTIBULAR DISORDER; WORD RECOGNITION;

AMINOGLYCOSIDES; ANIMALS; ANTI-BACTERIAL AGENTS; COCHLEA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HAIR CELLS; HEARING DISORDERS; HUMANS; INCIDENCE; MENIERE'S DISEASE; MUTATION; RISK ASSESSMENT; RISK FACTORS; RNA; RNA, RIBOSOMAL; VESTIBULE;

EID: 33846183562     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207779313731     Document Type: Review

References (108)

1. Roland JT Jr, Cohen NL. Vestibular and auditory ototoxicity. In: Cummings CW, Frederickson JM, Harker LA, Krause CJ, Schuller DF, Richardson MA Eds, Otolaryngology & Head and Neck Surgery, 3rd ed. St. Louis, Mosby, 1998; 3186-97.
2. Selimoglu E, Kalkandelen S, Erdogan F. Comparative vestibulotoxicity of different aminoglycosides in the Guinea pigs. Yonsei Med J 2003; 44: 517-22.
3. Haynes DS. Topical antibiotics: strategies for avoiding ototoxicity. Ear Nose Throat J 2004; 83: 12-4.
4. Strupp M, Arbusow V. Acute vestibulopathy. Curr Opin Neurol 2001; 14: 11-20.
5. Segal JA, Skolnick P. Polyamine-like actions of aminoglycosides and aminoglycoside derivatives at NMDA receptors. Eur J Pharmacol 1998; 347: 311-7.
6. Meyers RM. Ototoxic effects of gentamicin. Arch Otolaryngol 1970; 95: 160-2.
7. Kalkandelen S, Selimoglu E, Erdogan F, Ucuncu H, Altas E. Comparative cochlear toxicities of streptomycin, gentamicin, amikacin and netilmicin in guinea-pigs. J Int Med Res 2002; 30: 406-12.
8. Lundy LB, Graham MD. Ototoxicity and ototopical medications: A survey of otolaryngologists. Am J Otol 1993; 14: 141-6.
9. Roland PS. Clinical ototoxicity of topical antibiotic drops. Otolaryngol Head Neck Surg 1994; 110: 598-602.
10. Bath AP, Walsh RM, Bance ML, Rutka JA. Ototoxicity of topical gentamicin preparations. Laryngoscope 1999; 109: 1088-93.
11. Black FO, Pesznecker S, Stallings V. Permanent gentamicin vestibulotoxicity. Otol Neurotol 2004; 25: 559-69.
12. Matz G, Rybak L, Roland PS, Hamiley M, Friedman R, Manolidis S, et al. Ototoxicity of ototopical antibiotic drops in humans. Otolaryngol Head Neck Surg 2004; 130: S79-82.
13. Aust G. Vestibulotoxicity and ototoxicity of gentamicin in newborns at risk. Int Tinnitus J 2001; 7: 27-9.
14. Aust G, Schneider D. Vestibular toxicity of gentamycin in newborn infants. Laryngorhinootologie 2001; 80: 173-6.
15. Rybak LP, Kelly T. Ototoxicity: bioprotective mechanisms. Curr Opin Otolaryngol Head Neck Surg 2003; 11: 328-33.
16. Walker EM Jr, Fazekas-May MA, Bowen WR. Nephrotoxic and ototoxic agents. Clin Lab Med 1990; 10: 323-54.
17. Roland PS. New developments in our understanding of ototoxicity. Ear Nose Throat J 2004; 83: 15-6.
18. Bodmer D, Brors D, Pak P, Bodmer M, Ryan AF. Gentamicin-induced hair cell death is not dependent on the apoptosis receptor Fas. Laryngoscope 2003; 113: 452-5.
19. Lei L, Wang J, Huang X. Correlation between expression of Fas protein and hair cell apoptosis in basilar papilla of chicken. Lin Chuang Er Bi Yan Hou Ke Za Zhi 2002; 16: 297-9.
20. Dehne N, Rauen U, de Groot H, Lautermann J. Involvement of the mitochondrial permeability transition in gentamicin ototoxicity. Hear Res 2002; 169: 47-55.
21. Jacotot E, Costantini P, Laboureau E, Zamzami N, Susin SA, Kroemer G. Mitochondrial membrane permeabilization during the apoptotic process. Ann N Y Acad Sci 1999; 887: 18-30.
22. Ylikoski J, Xing-Qun L, Virkkala J, Pirvola U. Blockade of c-JUN N-terminal kinase pathway attenuates gentamicin-induced cochlear and vestibular hair cell death. Hear Res 2002; 166: 33-43.
23. Schacht J. Antioxidant therapy attenuates aminoglycoside-induced hearing loss. Ann N Y Acad Sci. 1999; 884: 125-30.
24. Lesniak W, Pecoraro VL, Schacht J. Ternary complexes of gentamicin with iron and lipid catalyze formation of reactive oxygen species. Chem Res Toxicol 2005; 18: 357-64.
25. Priuska E, Schacht J. Formation of free radicals by gentamicin and iron and evidence of an iron/gentamicin complex. Biochem Pharmacol 1995; 50: 1749-52.
26. Sha SH, Schacht J. Formation of reactive oxygen species following bioactivation of gentamicin. Free Radical Biol Med 1999; 26: 341-7.
27. Priuska E, Clark-Baldwin K, Pecoraro V, Schacht J. NMR-studies of iron-gentamicin complexes and the implications for aminoglycoside toxicity. Inorg Chim Acta 1998; 273: 85-91.
28. Lesniak W, Harris WR, Yudenfreud-Kraviz J, Schacht J, Pecoraro VL. Solution chemistry of copper(II)-gentamicin complexes. Relevance to metal-related aminoglycoside toxicity. Inorg Chem 2003; 42: 1420-9.
29. Jiang H, Sha SH Schacht J. The NF-κB pathway protects cochlear hair cells from aminoglycoside-induced ototoxicity. J Neurosci Res 2005; 79: 644-51.
30. Hirose K, Westrum LE, Stone JS, Zirpel L, Rubel EW. Dynamic studies of ototoxicity in mature avian auditory epithelium. Ann N Y Acad Sci 1999; 884: 389-409.
31. Ding D, Stracher A, Salvi R. Leupeptin protects cochlear and vestibular hair cells from gentamicin ototoxicity. Hear Res 2002, 164: 115-26.
32. Smith PF. Are vestibular hair cells excited to death by aminoglycoside antibiotics? J Vestib Res 2000; 10: 1-5.
33. Basile AS, Huang JM, Xie C, Webster D, Berlin C, Skolnick P. N-methyl-D-aspartate antagonists limit aminoglycoside antibiotic-induced hearing loss. Nat Med 1996; 2: 1338-43.
34. Bienkowski P, Scinska A, Kostowski W, Koros E, Kukwa A. Ototoxic mechanism of aminoglycoside antibiotics-role of glutaminergic NMDA receptors. Pol Merkuriusz Lek 2000; 9: 713-5.
35. Segal JA, Harris BD, Kustova Y, Basile A, Skolnick P. Aminoglycoside neurotoxicity involves NMDA receptor activation. Brain Res 1999; 815: 270-7.
36. Becvarovski Z. Absorption of intratympanic topical antibiotics. Ear Nose Throat J 2004; 83: 18-9.
37. Alzamil KS, Linthicum FH, Jr. Extraneous round window membranes and plugs: Possible effect on intratympanic therapy. Ann Otol Rhinol Laryngol 2000; 109: 30-2.
38. Wersall J, Lundquist PG, Bjorkroth DB. Ototoxicity of gentamicin. J Infect Dis 1969; 119: 410-6.
39. Roland PS, Rybak L, Hannley M, Matz G, Stewart MG, Manolidis S, et al. Animal ototoxicity of topical antibiotics and the relevance to clinical treatment of human subjects. Otolaryngol Head Neck Surg 2004; 130: S57-78.
40. Goycoolea MV. The round window membrane under normal and pathological conditions. Acta Otolaryngol Suppl 1992; 493: 43-55.
41. Goycoolea MV, Clinical aspects of round window membrane permeability under normal and pathological conditions. Acta Otolaryngol 2002; 121: 437-47.
42. Lundman LA, Holmquist L, Bagger-Sjoback D. Round window membrane permeability. An in vitro model. Acta Otolaryngol 1987; 104: 472-80.
43. Fischel-Ghodsian N. Genetic factors in aminoglycoside toxicity. Ann N Y Acad Sci 1999; 884: 99-109.
44. Tang HY, Hutcheson E, Neill S, Drummond-Borg M, Speer M, Alford RL. Genetic susceptibility to aminoglycoside ototoxicity: how many are at risk? Genet Med 2002; 4: 336-45.
45. Gurtler N, Schmuziger N, Kim Y, Mhatre AN, Jungi M, Lalwani AK. Audiologic testing and molecular analysis of 12S rRNA in patients receiving aminoglycosides. Laryngoscope 2005; 115: 640-4.
46. Guan MX, Fischel-Ghodsian N, Attardi G. A biochemical basis for the inherited susceptibility to aminoglycoside ototoxicity. Hum Mol Genet 2000; 9: 1787-93.
47. Ke X, Qi Y, Gu Z, Zhang Z, Zhang W, Jiang S, et al. Aminoglycoside ototoxicity associated with mitochondrial DNA mutation. Lin Chuang Er Bi Yan Hou Ke Za Zhi 1999; 13: 195-7.
48. Gallo-Teran J, Morales-Angulo C, del Castillo I, Villamar M, Moreno-Pelayo MA, Garcia-Mantilla J, et al. Incidence of A1555G mutations in the mitochondrial DNA and 35delG in the GJB2 gene (connexin-26) in families with late onset non-syndromic sensorineural hearing loss from Cantabria. Acta Otorrinolaringol Esp 2002; 53: 563-71.
49. Bacino C, Prezant TR, Bu X, Fournier P, Fischel-Ghodsian N. Susceptibility mutations in the mitochondrial small ribosomal RNA gene in aminoglycoside induced deafness. Pharmacogenetics 1995; 5: 165-72.
50. Casano RAMS, Johnson DF, Bykhovskaya Y, Torricelli F, Bigozzi M, Fischel-Ghodsian N. Inherited susceptibility to aminoglycoside ototoxicity: genetic heterogeneity and clinical implications. Am J Otolaryngol 1999; 20: 151-6.
51. Yamasoba T, Tsukuda K. Ototoxicity after use of neomycin eardrops is unrelated to A1555G point mutation in mitochondrial DNA. J Laryngol Otol 2004; 118: 546-50.
52. Fischel-Ghodsian N, Prezant TR, Chaltraw WE, Wendt KA, Nelson RA, Arnos KS, et al. Mitochondrial gene mutation is a significant predisposing factor in aminoglycoside ototoxicity. Am J Otolarynol 1997; 18: 173-8.
53. Scrimshaw BJ, Faed JM, Tate WP, Yun K. The frequency in New Zealand of a mitochondrial DNA mutation (1555 A to G) associated with aminoglycoside-induced hearing loss. N Z Med J 1999; 112: 216-7.
54. Christensen EF, Reiffenstein JC, Madissoo H. Comparative ototoxicity of amikacin and gentamicin in cats. Antimicrob Agents Chemother 1977; 12: 178-84.
55. Federspil P, Schatzle W, Tiesler E. Pharmacokinetics and ototoxicity of gentamicin, tobramicin and amikacin. J Infect Dis 1976; 134: 200-5.
56. Hawkins JE, Beger V, Aran J. Antibiotic insults to Corti's organ. In: Graham AB Ed, Sensorineural Hearing Processes and Disorders, New York, Little Brown & Co., 1967; 411-25.
57. Lindsay JR, Proctor LR, Work WP. Histopathologic inner ear changes in deafness due to neomycin in a human. Laryngoscope 1960; 70: 382-92.
58. Aran JM, Erre JP, Guilhaume A, Aurousseau C. The comparative ototoxicities of gentamicin, tobramycin and dibekacin in the guinea pig. A functional and morphological cochlear and vestibular study. Acta Otolaryngol Suppl 1982; 390: 1-30.
59. Wanamaker HH, Gruenwald L, Dam KJ, Ogata Y, Slepecky N. Dose-related vestibular and cochlear effects of transtympanic gentamicin. Am J Otol 1998; 19: 170-9.
60. Pyykko I, Ishizaki H, Kaasinen S, Aalto H. Intratympanic gentamicin in bilateral Meniere's disease. Otolaryngol Head Neck Surg 1994; 110: 162-7.
61. Kimura R, Iverson N, Sothord R: Selective lesions of the vestibular labyrinth. Ann Otol Rhinol Laryngol 1988; 97: 577-84.
62. Norris C, Amedee RG, Risey JA, Shea JJ. Selective chemical vestibulectomy. Am J Otol 1990; 6: 395-400.
63. Kimura RS, Lee KS, Nye CL, Trehey JA. Effects of systemic and lateral semicircular canal administration of aminoglycosides on normal and hydropic inner ears. Acta Otolaryngol 1991; 111: 1021-30.
64. Silverstein H. Streptomycin treatment for Meniere's disease. Ann Otol Rhinol Laryngol 1984: 112: 44-8.
65. Parnes L, Riddell D. Irritative spontaneous nystagmus following intratympanic gentamicin for Meniere's disease. Laryngoscope 1993; 103: 745-9.
66. Anniko M. Aspects on the ototoxic potential of netilmicin. Acta Otolaryngol (Stockh) 1983; 96: 75-89.
67. Federspil P. Ototoxicity and nephrotoxicity of netilmicin. Infection 1976; 4: 211.
68. Bamonte F, Parravicini L, Arpini A. Histological evaluation of ototoxic reaction due to some aminoglycoside antibiotics. Arch Otorhinolaryngol 1980; 228: 163-70.
69. Proctor LR, el-Kashef Y. The use of streptomycin to induce unilateral ablatic vestibular function in the rat: a preliminary report. Am J Otol 1989; 10: 188-97.
70. Kitasato I, Yokota M, Inouye S, Igarashi M. Comparative ototoxicity of ribostamycin, dactimicin, dibekacin, kanamycin, amikacin, tobramycin, gentamicin, sisomicin and netilmicin in the inner ear of guinea pigs. Chemotherapy 1990; 36: 155-68.
71. Lerner SA, Matz GJ. Aminoglycoside ototoxicity. Am J Otolaryngol 1980; 1: 169-79.
72. Baloh RW, Honrubia V, Yee RD, Hess K. Changes in the human vestibulo-ocular reflex after loss of peripheral sensitivity. Ann Neurol 1984; 16: 222-8.
73. Black FO, Peterka RJ, Elardo SM. Vestibular reflex changes following aminoglycoside induced ototoxicity. Laryngoscope 1987; 97: 582-6.
74. Nakagawa T, Yamane H, Takayama M, Sunami K, Nakai Y. Dose-dependent response of vestibular hair cells of guinea pigs following streptomycin ototoxication. Acta Otolaryngol 1998; 118: 530-3.
75. Tsuji K, Velazquez-Villasenor L, Rauch SD, Glynn RJ, Wall C 3rd, Merchant SN. Temporal bone studies of the human peripheral vestibular system. Aminoglycoside ototoxicity. Ann Otol Rhinol Laryngol Suppl 2000; 181: 20-5.
76. Lindeman HH. Regional differences in sensitivity of the vestibular sensory epithelia to ototoxic antibiotics. Acta Otolaryngol 1969; 67: 177-89.
77. Marais J, Rutka JA. Ototoxicity and topical eardrops. Clin Otolaryngol Allied Sci 1998; 23: 360-7.
78. Wanamaker HH, Slepecky NB, Cefaratti LK, Ogata Y. Comparison of vestibular and cochlear ototoxicity from transtympanic streptomycin administration. Am J Otol 1999; 20: 457-64.
79. Wersall J. The ototoxic potential of netilmicin compared with amikacin. An animal study in guinea pigs. Scand J Infect Dis Suppl 1980; Suppl 23: 104-13.
80. Morizono T. Toxicity of ototopical drugs: animal modeling. Ann Otol Rhinol Laryngol 1990; 148: 42-5.
81. Ikeda K, Morizono T. Round window membrane permeability during experimental purulent otitis media: altered cortisporin ototoxicity. Ann Otol Rhinol Laryngol 1990; 148: 46-8.
82. Pickett BP, Shinn JB, Smith MF. Ear drop ototoxicity: reality or myth? Am J Otol 1997; 18: 782-9.
83. Brummett RE, Harris RF, Lindgren JA. Detection of ototoxicity from drugs applied topically to the middle ear space. Laryngoscope 1976; 86: 1177-87.
84. Goycoolea MV, Muchow D, Schachem P. Experimental studies on round window structure: Function and permeability. Laryngoscope 1988; 44: 1-20.
85. Galloe AM, Graudal N, Christensen HR, Kampmann JP. Aminoglycosides: single or multiple daily dosing? Eur J Clin Pharmacol 1995; 49: 39-43.
86. Munckhof WJ, Grayson ML, Turnidge JD. A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses. J Antimicrob Chemother 1996; 37: 645-63.
87. Raz R, Adawi M, Romano S. Intravenous administration of gentamicin once daily vs. thrice daily in adults. Eur J Clin Microbiol Infect Dis 1995; 14: 88-91.
88. Bates RD, Nahata MC. Once-daily administration of aminoglycosides. Ann Pharmacother 1994; 28: 757-66.
89. Elhanan K, Siplovich L, Raz R. Gentamicin once-daily vs. thrice-daily in children. J Antimicrob Chemother 1992; 35: 327-32.
90. Contopoulos-Ioannidis DG, Giotis ND, Baliatsa DV, Ioannidis JP. Extended-interval aminoglycoside administration for children: a meta-analysis. Pediatrics 2004; 114: e111-8.
91. Barclay ML, Kirkpatrick CM, Begg EJ. Once daily aminoglycoside therapy. Is it less toxic than multiple daily doses and how should it be monitored? Clin Pharmacokinet 1999; 36: 89-98.
92. Ali MZ, Goetz MB. A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis 1997; 24: 796-809.
93. Bailey TC, Little JR, Littenberg B, Reichley RM, Dunagan WC. A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis 1997; 24: 786-95.
94. Blaser J, Konig C. Once-daily dosing of aminoglycosides. Eur J Clin Microbiol Infect Dis 1995; 14: 1029-38.
95. Wu WJ, Sha SH, Schacht J. Recent advances in understanding aminoglycoside ototoxicity and its prevention. Audiol Neurootol 2002; 7: 171-4.
96. Conlon BJ, Perry BP, Smith DW. Attenuation of neomycin ototoxicity by iron chelation. Laryngoscope 1998; 108: 284-7.
97. Song BB, Sha SH, Schacht J. Iron chelators protect from aminoglycoside-induced cochleo- and vestibulo-toxicity. Free Radic Biol Med 1998; 25: 189-95.
98. Sinswat P, Wu WJ, Sha SH, Schacht J. Protection from ototoxicity of intraperitoneal gentamicin in guinea pig. Kidney Int 2000; 58: 2525-32.
99. Conlon BJ, Smith DW. Topical aminoglycoside ototoxicity: attempting to protect the cochlea. Acta Otolaryngol 2000; 120: 596-9.
100. Sha SH, Schacht J. Salicylate attenuates gentamicin-induced ototoxicity. Lab Invest 1999; 79: 807-13.
101. Sha SH, Schacht J. Antioxidants attenuate gentamicin-induced free-radical formation in vitro and ototoxicity in vivo. D-methionine is a potential protectant. Hear Res 2000; 142: 34-40.
102. Mizuta K, Saito A, Watanabe T, Nagura M, Arakawa M, Shimizu F, Hoshino T. Ultrastructural localization of megalin in the rat cochlear duct. Hear Res 1999; 129: 83-91.
103. Forge A, Schacht J. Aminoglycoside antibiotics. Audiol Neurootol 2000; 5: 3-22.
104. Schuknecht HF. Ablation therapy in the management of Meniere's disease. Acta Otolaryngol 1957; 132: 1-42.
105. Biakley BW. Update on intratympanic gentamicin for Meniere's disease. Laryngoscope 2000; 110: 236-40.
106. Kaplan DM, Hehar SS, Bance ML, Rutka JA. Intentional ablation of vestibular function using commercially available topical gentamicin-betamethasone eardrops in patients with Meniere's disease: Further evidence for topical eardrop ototoxicity. Laryngoscope 2002; 112: 689-95.
107. Cohen-Kerem R, Kisilevsky V, Einarson TR, Kozer E, Koren G, Rutka JA. Intratympanic gentamicin for Meniere's disease: a meta-analysis. Laryngoscope 2004; 114: 2085-91.
108. Bottrill I, Wills AD, Mitchell AL. Intratympanic gentamicin for unilateral Meniere's disease: results of therapy. Clin Otolaryngol Allied Sci 2003; 28: 133-41.